Contraception and gynaecological care

Sharon Cameron
Best practice & research. Clinical obstetrics & gynaecology · 2009 · vol. 23(2) , pp. 211–220 · doi:10.1016/j.bpobgyn.2008.11.003 · PMID:19147411 · W2125114790
Review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This paper reviews the current landscape of contraception and gynecological care, discussing available methods and their associated benefits and risks.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Hormonal contraception, through suppression of ovarian activity or endometrial proliferation, can be used to treat and prevent a range of gynaecological disorders. There is evidence to support the effectiveness of the levonorgestrel intra-uterine system (LNG-IUS), combined oral contraceptive pill (COC) and progestogen-only injectable depot-medroxyprogesterone acetate for treating heavy menstrual bleeding and dysmenorrhoea. COCs are also an effective treatment for acne and hirsuitism, and may lessen the symptoms of premenstrual syndrome. There is good evidence that COCs can significantly reduce the risk of both ovarian and endometrial cancer. There is also some evidence that COCs may prevent ovarian cysts, endometrial hyperplasia and fibroids. The LNG-IUS may be used as endometrial protection in women using hormone replacement therapy or tamoxifen. This chapter will deal with the evidence for both treatment and prevention of a range of gynaecological disorders of different hormonal contraceptive methods.

My notes (saved in your browser only)

MeSH descriptors

Contraceptive Agents, Female Dysmenorrhea Endometritis Hirsutism Uterine Neoplasms Confidence Intervals Contraceptive Agents, Female Dysmenorrhea Dysmenorrhea Endometritis Endometritis Female Hirsutism Hirsutism Humans Uterine Neoplasms Uterine Neoplasms Women's Health

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (71)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:06:07.402396+00:00
unpaywall
last seen: 2026-10-12T06:33:14.382917+00:00
License: CC0 · commercial use OK